Advertisement

Hereditary Diffuse Gastric Cancer

Chapter
Part of the Cancer Treatment and Research book series (CTAR, volume 155)

Abstract

Gastric cancer is one of the world’s leading causes of cancer mortality. A small percentage of cases can be attributed to heritable mutations in highly penetrant cancer susceptibility genes. In this chapter we will focus on the genetic cause of hereditary diffuse gastric cancer (HDGC). Until 10 years ago, individuals from these families lived with the uncertainty of developing lethal gastric cancer. Today, HDGC families can be identified, tested for causative mutations in CDH1, and for those families where a pathogenic mutation can be identified, prophylactic total gastrectomy can be implemented in asymptomatic mutation carriers who elect to virtually eliminate their risk of developing this lethal disease.

Keywords

Gastric Cancer Pylorus Infection Lynch Syndrome Signet Ring Cell Gastric Cancer Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Guilford P, Hopkins J, Harraway J et al (1998) E-cadherin germline mutations in familial gastric cancer. Nature 392:402–405PubMedGoogle Scholar
  2. 2.
    Kaurah P, MacMillan A, Boyd N et al (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA 297:2360–2372PubMedGoogle Scholar
  3. 3.
    Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology 121:1348–1353PubMedGoogle Scholar
  4. 4.
    Keller G, Vogelsang H, Becker I et al (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. Am J Pathol 155:337–342PubMedGoogle Scholar
  5. 5.
    Suriano G, Yew S, Ferreira P et al (2005) Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. Clin Cancer Res 11:5401–5409PubMedGoogle Scholar
  6. 6.
    Brooks-Wilson AR, Kaurah P, Suriano G et al (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. J Med Genet 41:508–517PubMedGoogle Scholar
  7. 7.
    Huntsman DG, Carneiro F, Lewis FR et al (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. N Engl J Med 344:1904–1909PubMedGoogle Scholar
  8. 8.
    Lewis FR, Mellinger JD, Hayashi A et al (2001) Prophylactic total gastrectomy for familial gastric cancer. Surgery 130:612–617, discussion 617–619PubMedGoogle Scholar
  9. 9.
    Chun YS, Lindor NM, Smyrk TC et al (2001) Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated? Cancer 92:181–187PubMedGoogle Scholar
  10. 10.
    Carneiro F, Huntsman DG, Smyrk TC et al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 203:681–687PubMedGoogle Scholar
  11. 11.
    Charlton A, Blair V, Shaw D, Parry S, Guilford P, Martin IG (2004) Hereditary diffuse gastric cancer: predominance of multiple foci of signet ring cell carcinoma in distal stomach and transitional zone. Gut 53:814–820PubMedGoogle Scholar
  12. 12.
    Shaw D, Blair V, Framp A et al (2005) Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? Gut 54:461–468PubMedGoogle Scholar
  13. 13.
    Gaya DR, Stuart RC, McKee RF, Going JJ, Davidson R, Stanley AJ (2005) E-cadherin mutation-associated diffuse gastric adenocarcinoma: penetrance and non-penetrance. Eur J Gastroenterol Hepatol 17:1425–1428PubMedGoogle Scholar
  14. 14.
    Blair V, Martin I, Shaw D et al (2006) Hereditary diffuse gastric cancer: diagnosis and management. Clin Gastroenterol Hepatol 4:262–275PubMedGoogle Scholar
  15. 15.
    Francis WP, Rodrigues DM, Perez NE, Lonardo F, Weaver D, Webber JD (2007) Prophylactic laparoscopic-assisted total gastrectomy for hereditary diffuse gastric cancer. JSLS 11:142–147PubMedGoogle Scholar
  16. 16.
    Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. Ann Surg 245:873–879PubMedGoogle Scholar
  17. 17.
    Barber ME, Save V, Carneiro F et al (2008) Histopathological and molecular analysis of gastrectomy specimens from hereditary diffuse gastric cancer patients has implications for endoscopic surveillance of individuals at risk. J Pathol 216:286–294PubMedGoogle Scholar
  18. 18.
    Rogers WM, Dobo E, Norton JA et al (2008) Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. Am J Surg Pathol 32:799–809PubMedGoogle Scholar
  19. 19.
    Hebbard PC, Macmillan A, Huntsman D et al (2009) Prophylactic total gastrectomy (PTG) for hereditary diffuse gastric cancer (HDGC): the Newfoundland experience with 23 patients. Ann Surg Oncol 16:1890–1895PubMedGoogle Scholar
  20. 20.
    LAUREN P (1965) The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 64:31–49PubMedGoogle Scholar
  21. 21.
    Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. World J Gastroenterol 12:354–362PubMedGoogle Scholar
  22. 22.
    Correa P (1992) Human gastric carcinogenesis: a multistep and multifactorial process – first American cancer society award lecture on cancer epidemiology and prevention. Cancer Res 52:6735–6740PubMedGoogle Scholar
  23. 23.
    Oliveira C, Moreira H, Seruca R et al (2005) Role of pathology in the identification of hereditary diffuse gastric cancer: Report of a Portuguese family. Virchows Arch 446:181–184Google Scholar
  24. 24.
    Humar B, Fukuzawa R, Blair V et al (2007) Destabilized adhesion in the gastric proliferative zone and c-src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 67:2480–2489PubMedGoogle Scholar
  25. 25.
    Hamilton SR, Aaltonen LA (2000) Pathology and genetics. Tumours of the digestive system, WHO classification of tumours, vol 2. IARC Press, France, pp 35–52Google Scholar
  26. 26.
    Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedGoogle Scholar
  27. 27.
    Suerbaum S, Michetti P (2002) Helicobacter pylori infection. N Engl J Med 347:1175–1186PubMedGoogle Scholar
  28. 28.
    Uemura N, Okamoto S, Yamamoto S et al (2001) Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784–789PubMedGoogle Scholar
  29. 29.
    Helicobacter and Cancer Collaborative Group (2001) Gastric cancer and helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 49:347–353Google Scholar
  30. 30.
    Ferreira AC, Isomoto H, Moriyama M, Fujioka T, Machado JC, Yamaoka Y (2008) Helicobacter and gastric malignancies. Helicobacter 13(Supplement 1):28–34PubMedGoogle Scholar
  31. 31.
    Stein M, Rappuoli R, Covacci A (2000) Tyrosine phosphorylation of the helicobacter pylori CagA antigen after cag-driven host cell translocation. Proc Natl Acad Sci U S A 97:1263–1268PubMedGoogle Scholar
  32. 32.
    Ohnishi N, Yuasa H, Tanaka S et al (2008) Transgenic expression of helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Natl Acad Sci U S A 105:1003–1008PubMedGoogle Scholar
  33. 33.
    El-Omar EM, Carrington M, Chow WH et al (2000) Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404:398–402PubMedGoogle Scholar
  34. 34.
    El-Omar EM, Rabkin CS, Gammon MD et al (2003) Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124:1193–1201PubMedGoogle Scholar
  35. 35.
    Canedo P, Corso G, Pereira F et al (2008) The interferon gamma receptor 1 (IFNGR1) –56C/T gene polymorphism is associated with increased risk of early gastric carcinoma. Gut 57:1504–1508PubMedGoogle Scholar
  36. 36.
    Forman D, Burley VJ (2006) Gastric cancer: global pattern of the disease and an overview of environmental risk factors. Best Pract Res Clin Gastroenterol 20:633–649PubMedGoogle Scholar
  37. 37.
    Liu C, Russell RM (2008) Nutrition and gastric cancer risk: an update. Nutr Rev 66:237–249PubMedGoogle Scholar
  38. 38.
    McMichael AJ, McCall MG, Hartshorne JM, Woodings TL (1980) Patterns of gastro-intestinal cancer in European migrants to Australia: the role of dietary change. Int J Cancer 25:431–437PubMedGoogle Scholar
  39. 39.
    Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the united states, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med 128:765–770PubMedGoogle Scholar
  40. 40.
    Roosendaal R, Kuipers EJ, Buitenwerf J et al (1997) Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 92:1480–1482PubMedGoogle Scholar
  41. 41.
    Borch K, Jonsson B, Tarpila E et al (2000) Changing pattern of histological type, location, stage and outcome of surgical treatment of gastric carcinoma. Br J Surg 87:618–626PubMedGoogle Scholar
  42. 42.
    Kamangar F, Dawsey SM, Blaser MJ et al (2006) Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with helicobacter pylori seropositivity. J Natl Cancer Inst 98:1445–1452PubMedGoogle Scholar
  43. 43.
    Tatemichi M, Sasazuki S, Inoue M, Tsugane S, Japan Public Health Center Study Group (2008) Different etiological role of helicobacter pylori (hp) infection in carcinogenesis between differentiated and undifferentiated gastric cancers: a nested case-control study using IgG titer against hp surface antigen. Acta Oncol 47:360–365PubMedGoogle Scholar
  44. 44.
    Perri F, Cotugno R, Piepoli A et al (2007) Aberrant DNA methylation in non-neoplastic gastric mucosa of H. pylori infected patients and effect of eradication. Am J Gastroenterol 102:1361–1371PubMedGoogle Scholar
  45. 45.
    Kaise M, Yamasaki T, Yonezawa J, Miwa J, Ohta Y, Tajiri H (2008) CpG island hypermethylation of tumor-suppressor genes in H. pylori-infected non-neoplastic gastric mucosa is linked with gastric cancer risk. Helicobacter 13:35–41PubMedGoogle Scholar
  46. 46.
    Brenner H, Arndt V, Sturmer T, Stegmaier C, Ziegler H, Dhom G (2000) Individual and joint contribution of family history and helicobacter pylori infection to the risk of gastric carcinoma. Cancer 88:274–279PubMedGoogle Scholar
  47. 47.
    Lee KJ, Inoue M, Otani T et al (2006) Gastric cancer screening and subsequent risk of gastric cancer: a large-scale population-based cohort study, with a 13-year follow-up in Japan. Int J Cancer 118:2315–2321PubMedGoogle Scholar
  48. 48.
    Sugano K (2008) Gastric cancer: pathogenesis, screening, and treatment. Gastrointest Endosc Clin N Am 18:513–522PubMedGoogle Scholar
  49. 49.
    Tsukamoto Y, Uchida T, Karnan S et al (2008) Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer. J Pathol 216:471–482PubMedGoogle Scholar
  50. 50.
    Wang LD, Qin YR, Fan ZM et al (2006) Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern china. Dis Esophagus 19:459–467PubMedGoogle Scholar
  51. 51.
    Kang JU, Kang JJ, Kwon KC et al (2006) Genetic alterations in primary gastric carcinomas correlated with clinicopathological variables by array comparative genomic hybridization. J Korean Med Sci 21:656–665PubMedGoogle Scholar
  52. 52.
    Kurihara Y, Ghazizadeh M, Bo H et al (2002) Genome-wide screening of laser capture microdissected gastric signet ring cell carcinomas. J Nippon Med Sch 69:235–242PubMedGoogle Scholar
  53. 53.
    Lee SH, Kim HS (2003) Sequence analyses of aberrant FHIT transcripts in gastric cancer cell lines. Korean J Gastroenterol 42:476–483PubMedGoogle Scholar
  54. 54.
    Rocco A, Schandl L, Chen J et al (2003) Loss of FHIT protein expression correlates with disease progression and poor differentiation in gastric cancer. J Cancer Res Clin Oncol 129:84–88PubMedGoogle Scholar
  55. 55.
    Kim JH, Kim MA, Lee HS, Kim WH (2009) Comparative analysis of protein expressions in primary and metastatic gastric carcinomas. Hum Pathol 40:314–322PubMedGoogle Scholar
  56. 56.
    Barros-Silva JD, Leitao D, Afonso L et al (2009) Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 100:487–493PubMedGoogle Scholar
  57. 57.
    Myllykangas S, Junnila S, Kokkola A et al (2008) Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int J Cancer 123:817–825PubMedGoogle Scholar
  58. 58.
    Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629PubMedGoogle Scholar
  59. 59.
    Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26:2157–2165PubMedGoogle Scholar
  60. 60.
    Migliavacca M, Ottini L, Bazan V et al (2004) TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome. J Cell Physiol 200:476–485PubMedGoogle Scholar
  61. 61.
    Imyanitov EN (2009) Gene polymorphisms, apoptotic capacity and cancer risk. Hum Genet 125:239–246PubMedGoogle Scholar
  62. 62.
    Kim JG, Sohn SK, Chae YS et al (2008) TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin. Cancer Chemother Pharmacol 64(2):355–360PubMedGoogle Scholar
  63. 63.
    D‘Errico M, de Rinaldis E, Blasi MF et al (2009) Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. Eur J Cancer 45:461–469PubMedGoogle Scholar
  64. 64.
    Falchetti M, Saieva C, Lupi R et al (2008) Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. Hum Pathol 39:925–932PubMedGoogle Scholar
  65. 65.
    Leung SY, Yuen ST, Chung LP, Chu KM, Chan AS, Ho JC (1999) hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res 59:159–164PubMedGoogle Scholar
  66. 66.
    Wu MS, Lee CW, Shun CT et al (2000) Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. Genes Chromosomes Cancer 27:403–411PubMedGoogle Scholar
  67. 67.
    Lynch HT, Grady W, Suriano G, Huntsman D (2005) Gastric cancer: new genetic developments. J Surg Oncol 90:114–133, discussion 133PubMedGoogle Scholar
  68. 68.
    Mayer B, Johnson JP, Leitl F et al (1993) E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res 53:1690–1695PubMedGoogle Scholar
  69. 69.
    Gamallo C, Palacios J, Suarez A et al (1993) Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 142:987–993PubMedGoogle Scholar
  70. 70.
    Kadowaki T, Shiozaki H, Inoue M et al (1994) E-cadherin and alpha-catenin expression in human esophageal cancer. Cancer Res 54:291–296PubMedGoogle Scholar
  71. 71.
    Winter JM, Ting AH, Vilardell F et al (2008) Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res 14:412–418PubMedGoogle Scholar
  72. 72.
    Berx G, Becker KF, Hofler H, van Roy F (1998) Mutations of the human E-cadherin (CDH1) gene. Hum Mutat 12:226–237PubMedGoogle Scholar
  73. 73.
    Keller R (2002) Shaping the vertebrate body plan by polarized embryonic cell movements. Science 298:1950–1954PubMedGoogle Scholar
  74. 74.
    Geisbrecht ER, Montell DJ (2002) Myosin VI is required for E-cadherin-mediated border cell migration. Nat Cell Biol 4:616–620PubMedGoogle Scholar
  75. 75.
    Larue L, Ohsugi M, Hirchenhain J, Kemler R (1994) E-cadherin null mutant embryos fail to form a trophectoderm epithelium. Proc Natl Acad Sci U S A 91:8263–8267PubMedGoogle Scholar
  76. 76.
    Berx G, Staes K, van Hengel J et al (1995) Cloning and characterization of the human invasion suppressor gene E-cadherin (CDH1). Genomics 26:281–289PubMedGoogle Scholar
  77. 77.
    Shore EM, Nelson WJ (1991) Biosynthesis of the cell adhesion molecule uvomorulin (E-cadherin) in Madin-Darby canine kidney epithelial cells. J Biol Chem 266:19672–19680PubMedGoogle Scholar
  78. 78.
    Caldas C, Carneiro F, Lynch HT et al (1999) Familial gastric cancer: overview and guidelines for management. J Med Genet 36:873–880PubMedGoogle Scholar
  79. 79.
    Boller K, Vestweber D, Kemler R (1985) Cell-adhesion molecule uvomorulin is localized in the intermediate junctions of adult intestinal epithelial cells. J Cell Biol 100:327–332PubMedGoogle Scholar
  80. 80.
    Thoreson MA, Anastasiadis PZ, Daniel JM et al (2000) Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. J Cell Biol 148:189–202PubMedGoogle Scholar
  81. 81.
    Xiao K, Oas RG, Chiasson CM, Kowalczyk AP (2007) Role of p120-catenin in cadherin trafficking. Biochim Biophys Acta 1773:8–16PubMedGoogle Scholar
  82. 82.
    Van Aelst L, Symons M (2002) Role of rho family GTPases in epithelial morphogenesis. Genes Dev 16:1032–1054PubMedGoogle Scholar
  83. 83.
    Fujita Y, Hogan C, Braga VM (2006) Regulation of cell-cell adhesion by Rap1. Methods Enzymol 407:359–372PubMedGoogle Scholar
  84. 84.
    Shen Y, Hirsch DS, Sasiela CA, Wu WJ (2008) Cdc42 regulates E-cadherin ubiquitination and degradation through an epidermal growth factor receptor to src-mediated pathway. J Biol Chem 283:5127–5137PubMedGoogle Scholar
  85. 85.
    Stemmler MP, Hecht A, Kemler R (2005) E-cadherin intron 2 contains cis-regulatory elements essential for gene expression. Development 132:965–976PubMedGoogle Scholar
  86. 86.
    Gloushankova NA (2008) Changes in regulation of cell-cell adhesion during tumor transformation. Biochemistry (Mosc) 73:742–750Google Scholar
  87. 87.
    Sorkin BC, Jones FS, Cunningham BA, Edelman GM (1993) Identification of the promoter and a transcriptional enhancer of the gene encoding L-CAM, a calcium-dependent cell adhesion molecule. Proc Natl Acad Sci U S A 90:11356–11360PubMedGoogle Scholar
  88. 88.
    Li LC, Chui RM, Sasaki M et al (2000) A single nucleotide polymorphism in the E-cadherin gene promoter alters transcriptional activities. Cancer Res 60:873–876PubMedGoogle Scholar
  89. 89.
    Jenab M, McKay JD, Ferrari P et al (2008) CDH1 gene polymorphisms, smoking, helicobacter pylori infection and the risk of gastric cancer in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). Eur J Cancer 44:774–780PubMedGoogle Scholar
  90. 90.
    Corso G, Berardi A, Marrelli D et al (2009) CDH1 C-160A promoter polymorphism and gastric cancer risk. Eur J Cancer Prev 18:46–49PubMedGoogle Scholar
  91. 91.
    Wang GY, Lu CQ, Zhang RM, Hu XH, Luo ZW (2008) The E-cadherin gene polymorphism 160C–>A and cancer risk: a HuGE review and meta-analysis of 26 case-control studies. Am J Epidemiol 167:7–14PubMedGoogle Scholar
  92. 92.
    Humar B, Graziano F, Cascinu S et al (2002) Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Oncogene 21:8192–8195PubMedGoogle Scholar
  93. 93.
    Nasri S, More H, Graziano F et al (2008) A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population. BMC Cancer 8:138PubMedGoogle Scholar
  94. 94.
    Oliveira C, Bordin MC, Grehan N et al (2002) Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat 19:510–517PubMedGoogle Scholar
  95. 95.
    Oliveira C, Senz J, Kaurah P et al (2009) Germline CDH1 deletions in hereditary diffuse gastric cancer families. Hum Mol Genet 18(9):1545–1555PubMedGoogle Scholar
  96. 96.
    Frebourg T, Oliveira C, Hochain P et al (2006) Cleft lip/palate and CDH1/E-cadherin mutations in families with hereditary diffuse gastric cancer. J Med Genet 43:138–142PubMedGoogle Scholar
  97. 97.
    Strachan T, Read A (2003) Human molecular genetics, 3rd edn. Garland Science, OxfordGoogle Scholar
  98. 98.
    Vleminckx K, Vakaet L Jr, Mareel M, Fiers W, van Roy F (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66:107–119PubMedGoogle Scholar
  99. 99.
    Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G (1998) A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature 392:190–193PubMedGoogle Scholar
  100. 100.
    Bukholm IK, Nesland JM, Borresen-Dale AL (2000) Re-expression of E-cadherin, alpha-catenin and β-catenin, but not of gamma-catenin, in metastatic tissue from breast cancer patients [see comments]. J Pathol 190:15–19PubMedGoogle Scholar
  101. 101.
    Handschuh G, Candidus S, Luber B et al (1999) Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 18:4301–4312PubMedGoogle Scholar
  102. 102.
    Becker KF, Atkinson MJ, Reich U et al (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54:3845–3852PubMedGoogle Scholar
  103. 103.
    Machado JC, Oliveira C, Carvalho R et al (2001) E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20:1525–1528PubMedGoogle Scholar
  104. 104.
    Moll R, Mitze M, Frixen UH, Birchmeier W (1993) Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 143:1731–1742PubMedGoogle Scholar
  105. 105.
    Vos CB, Cleton-Jansen AM, Berx G et al (1997) E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 76:1131–1133PubMedGoogle Scholar
  106. 106.
    Oliveira C, Sousa S, Pinheiro H et al (2009) Quantification of epigenetic and genetic second hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. Gastroenterology 136(7):2137–2148PubMedGoogle Scholar
  107. 107.
    Yang J, Weinberg RA (2008) Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14:818–829PubMedGoogle Scholar
  108. 108.
    Berx G, Cleton-Jansen AM, Nollet F et al (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14:6107–6115PubMedGoogle Scholar
  109. 109.
    Christofori G, Semb H (1999) The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 24:73–76PubMedGoogle Scholar
  110. 110.
    Oda T, Kanai Y, Oyama T et al (1994) E-cadherin gene mutations in human gastric carcinoma cell lines. Proc Natl Acad Sci U S A 91:1858–1862PubMedGoogle Scholar
  111. 111.
    Grady WM, Willis J, Guilford PJ et al (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. Nat Genet 26:16–17PubMedGoogle Scholar
  112. 112.
    Barber M, Murrell A, Ito Y et al (2008) Mechanisms and sequelae of E-cadherin silencing in hereditary diffuse gastric cancer. J Pathol 216:295–306PubMedGoogle Scholar
  113. 113.
    Knudson AG Jr (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68:820–823PubMedGoogle Scholar
  114. 114.
    Orsulic S, Huber O, Aberle H, Arnold S, Kemler R (1999) E-cadherin binding prevents β-catenin nuclear localization and β-catenin/LEF-1-mediated transactivation. J Cell Sci 112(Pt 8):1237–1245PubMedGoogle Scholar
  115. 115.
    Aoki K, Taketo MM (2007) Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J Cell Sci 120:3327–3335PubMedGoogle Scholar
  116. 116.
    Novak A, Dedhar S (1999) Signaling through β-catenin and Lef/Tcf. Cell Mol Life Sci 56:523–537PubMedGoogle Scholar
  117. 117.
    He TC, Sparks AB, Rago C et al (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509–1512PubMedGoogle Scholar
  118. 118.
    Gottardi CJ, Gumbiner BM (2004) Distinct molecular forms of β-catenin are targeted to adhesive or transcriptional complexes. J Cell Biol 167:339–349PubMedGoogle Scholar
  119. 119.
    Barber M, Fitzgerald RC, Caldas C (2006) Familial gastric cancer – aetiology and pathogenesis. Best Pract Res Clin Gastroenterol 20:721–734PubMedGoogle Scholar
  120. 120.
    Geary J, Sasieni P, Houlston R et al (2007) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer 7(2):163–172PubMedGoogle Scholar
  121. 121.
    Douglas JA, Gruber SB, Meister KA et al (2005) History and molecular genetics of lynch syndrome in family G: a century later. JAMA 294:2195–2202PubMedGoogle Scholar
  122. 122.
    Cai SJ, Xu Y, Cai GX et al (2003) Clinical characteristics and diagnosis of patients with hereditary nonpolyposis colorectal cancer. World J Gastroenterol 9:284–287PubMedGoogle Scholar
  123. 123.
    Park YJ, Shin KH, Park JG (2000) Risk of gastric cancer in hereditary nonpolyposis colorectal cancer in Korea. Clin Cancer Res 6:2994–2998PubMedGoogle Scholar
  124. 124.
    Giardiello FM, Brensinger JD, Tersmette AC et al (2000) Very high risk of cancer in familial peutz-jeghers syndrome. Gastroenterology 119:1447–1453PubMedGoogle Scholar
  125. 125.
    Oliveira C, Ferreira P, Nabais S et al (2004) E-cadherin (CDH1) and p53 rather than SMAD4 and caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. Eur J Cancer 40:1897–1903PubMedGoogle Scholar
  126. 126.
    Keller G, Vogelsang H, Becker I et al (2004) Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet 41:e89PubMedGoogle Scholar
  127. 127.
    Jagelman DG, DeCosse JJ, Bussey HJ (1988) Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1:1149–1151PubMedGoogle Scholar
  128. 128.
    Shimoyama S, Aoki F, Kawahara M et al (2004) Early gastric cancer development in a familial adenomatous polyposis patient. Dig Dis Sci 49:260–265PubMedGoogle Scholar
  129. 129.
    Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94:1365–1372PubMedGoogle Scholar
  130. 130.
    Cancer Risks in BRCA2 Mutation Carriers (1999) Cancer risks in BRCA2 mutation carriers the breast cancer linkage consortium. J Natl Cancer Inst 91:1310–1316Google Scholar
  131. 131.
    Risch HA, McLaughlin JR, Cole DE et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 68:700–710PubMedGoogle Scholar
  132. 132.
    Study Group of Millennium Genome Project for Cancer, Sakamoto H, Yoshimura K et al (2008) Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet 40:730–740PubMedGoogle Scholar
  133. 133.
    JONES EG (1964) Familial gastric cancer. N Z Med J 63:287–296PubMedGoogle Scholar
  134. 134.
    Guilford PJ, Hopkins JB, Grady WM et al (1999) E-cadherin germline mutations define an inherited cancer syndrome dominated by diffuse gastric cancer. Hum Mutat 14:249–255PubMedGoogle Scholar
  135. 135.
    Gayther SA, Gorringe KL, Ramus SJ et al (1998) Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res 58:4086–4089PubMedGoogle Scholar
  136. 136.
    Richards FM, McKee SA, Rajpar MH et al (1999) Germline E-cadherin gene (CDH1) mutations predispose to familial gastric cancer and colorectal cancer. Hum Mol Genet 8:607–610PubMedGoogle Scholar
  137. 137.
    Shinmura K, Kohno T, Takahashi M et al (1999) Familial gastric cancer: clinicopathological characteristics, RER phenotype and germline p53 and E-cadherin mutations. Carcinogenesis 20:1127–1131PubMedGoogle Scholar
  138. 138.
    Yoon KA, Ku JL, Yang HK, Kim WH, Park SY, Park JG (1999) Germline mutations of E-cadherin gene in Korean familial gastric cancer patients. J Hum Genet 44:177–180PubMedGoogle Scholar
  139. 139.
    Ascano JJ, Frierson H Jr, Moskaluk CA et al (2001) Inactivation of the E-cadherin gene in sporadic diffuse-type gastric cancer. Mod Pathol 14:942–949PubMedGoogle Scholar
  140. 140.
    Dussaulx-Garin L, Blayau M, Pagenault M et al (2001) A new mutation of E-cadherin gene in familial gastric linitis plastica cancer with extra-digestive dissemination. Eur J Gastroenterol Hepatol 13:711–715PubMedGoogle Scholar
  141. 141.
    Yabuta T, Shinmura K, Tani M et al (2002) E-cadherin gene variants in gastric cancer families whose probands are diagnosed with diffuse gastric cancer. Int J Cancer 101:434–441PubMedGoogle Scholar
  142. 142.
    Humar B, Toro T, Graziano F et al (2002) Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Hum Mutat 19:518–525PubMedGoogle Scholar
  143. 143.
    Jonsson BA, Bergh A, Stattin P, Emmanuelsson M, Gronberg H (2002) Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 98:838–843PubMedGoogle Scholar
  144. 144.
    Sarrio D, Moreno-Bueno G, Hardisson D et al (2003) Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer 106:208–215PubMedGoogle Scholar
  145. 145.
    Wang Y, Song JP, Ikeda M, Shinmura K, Yokota J, Sugimura H (2003) Ile-leu substitution (I415L) in germline E-cadherin gene (CDH1) in Japanese familial gastric cancer. Jpn J Clin Oncol 33:17–20PubMedGoogle Scholar
  146. 146.
    Jiang Y, Wan YL, Wang ZJ, Zhao B, Zhu J, Huang YT (2004) Germline E-cadherin gene mutation screening in familial gastric cancer kindreds. Zhonghua Wai Ke Za Zhi 42:914–917PubMedGoogle Scholar
  147. 147.
    Karam R, Carvalho J, Bruno I et al (2008) The NMD mRNA surveillance pathway downregulates aberrant E-cadherin transcripts in gastric cancer cells and in CDH1 mutation carriers. Oncogene 27:4255–4260PubMedGoogle Scholar
  148. 148.
    Lee JH, Han SU, Cho H et al (2000) A novel germ line juxtamembrane met mutation in human gastric cancer. Oncogene 19:4947–4953PubMedGoogle Scholar
  149. 149.
    More H, Humar B, Weber W et al (2007) Identification of seven novel germline mutations in the human E-cadherin (CDH1) gene. Hum Mutat 28:203PubMedGoogle Scholar
  150. 150.
    Kim IJ, Park JH, Kang HC et al (2003) A novel germline mutation in the MET extracellular domain in a Korean patient with the diffuse type of familial gastric cancer. J Med Genet 40:e97PubMedGoogle Scholar
  151. 151.
    Pinheiro H, Bordeira-Carrico R, Seixas S et al (2010) Allele-specific CDH1 downregulation and hereditary diffuse gastric cancer. Hum Mol Genet 19:943–952Google Scholar
  152. 152.
    Oliveira C, de Bruin J, Nabais S et al (2004) Intragenic deletion of CDH1 as the inactivating mechanism of the wild-type allele in an HDGC tumour. Oncogene 23:2236–2240PubMedGoogle Scholar
  153. 153.
    Vidal-Puig A, Moller DE (1994) Comparative sensitivity of alternative single-strand conformation polymorphism (SSCP) methods. BioTechniques 17:490–492, 494, 496PubMedGoogle Scholar
  154. 154.
    Mullins FM, Dietz L, Lay M et al (2007) Identification of an intronic single nucleotide polymorphism leading to allele dropout during validation of a CDH1 sequencing assay: implications for designing polymerase chain reaction-based assays. Genet Med 9:752–760PubMedGoogle Scholar
  155. 155.
    van Kouwen MC, Drenth JP, Oyen WJ et al (2004) [18F]fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. Clin Cancer Res 10:6456–6459PubMedGoogle Scholar
  156. 156.
    Pacelli F, Papa V, Rosa F et al (2008) Four hundred consecutive total gastrectomies for gastric cancer: a single-institution experience. Arch Surg 143:769–775, discussion 775PubMedGoogle Scholar
  157. 157.
    Lynch HT, Kaurah P, Wirtzfeld D et al (2008) Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Cancer 112:2655–2663PubMedGoogle Scholar
  158. 158.
    Kaurah P, Fitzgerald R, Dwerryhouse S et al (2010) Pregnancy after prophylactic total gastrectomy. Fam CancerGoogle Scholar
  159. 159.
    Masciari S, Larsson N, Senz J et al (2007) Germline E-cadherin mutations in familial lobular breast cancer. J Med Genet 44(11):726–731PubMedGoogle Scholar
  160. 160.
    Schrader KA, Masciari S, Boyd N et al (2008) Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer 7:73–82PubMedGoogle Scholar
  161. 161.
    Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149–R156PubMedGoogle Scholar
  162. 162.
    Berx G, Van Roy F (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. Breast Cancer Res 3:289–293PubMedGoogle Scholar
  163. 163.
    Berx G, Cleton-Jansen AM, Strumane K et al (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 13:1919–1925PubMedGoogle Scholar
  164. 164.
    Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR (2001) Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer 92:404–408PubMedGoogle Scholar
  165. 165.
    Thull DL, Vogel VG (2004) Recognition and management of hereditary breast cancer syndromes. Oncologist 9:13–24PubMedGoogle Scholar
  166. 166.
    Rosman DS, Kaklamani V, Pasche B (2007) New insights into breast cancer genetics and impact on patient management. Curr Treat Options Oncol 8:61–73PubMedGoogle Scholar
  167. 167.
    Byrnes GB, Southey MC, Hopper JL (2008) Are the so-called low penetrance breast cancer genes, ATM, BRIP1, PALB2 and CHEK2, high risk for women with strong family histories? Breast Cancer Res 10:208PubMedGoogle Scholar
  168. 168.
    Smith RA, Saslow D, Sawyer KA et al (2003) American cancer society guidelines for breast cancer screening: update 2003. CA Cancer J Clin 53:141–169PubMedGoogle Scholar
  169. 169.
    Saslow D, Boetes C, Burke W et al (2007) American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57:75–89PubMedGoogle Scholar
  170. 170.
    Port ER, Park A, Borgen PI, Morris E, Montgomery LL (2007) Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol 14:1051–1057PubMedGoogle Scholar
  171. 171.
    Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–484PubMedGoogle Scholar
  172. 172.
    Land SR, Wickerham DL, Costantino JP et al (2006) Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 295:2742–2751PubMedGoogle Scholar
  173. 173.
    Wolmark N, Dunn BK (2001) The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP breast cancer prevention trial (P-1). Ann N Y Acad Sci 949:99–108PubMedGoogle Scholar
  174. 174.
    Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22:1055–1062PubMedGoogle Scholar
  175. 175.
    Barton MB, West CN, Liu IL et al (2005) Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr(35):61–66Google Scholar
  176. 176.
    Lodder LN, Frets PG, Trijsburg RW et al (2002) One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 73:97–112PubMedGoogle Scholar
  177. 177.
    Qiu LX, Li RT, Zhang JB et al (2009) The E-cadherin (CDH1) – 160 C/A polymorphism and prostate cancer risk: a meta-analysis. Eur J Hum Genet 17:244–249PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Pathology and Laboratory Medicine and Department of Medical GeneticsUniversity of British Columbia, British Columbia Cancer AgencyVancouverCanada
  2. 2.Department of Pathology and Laboratory Medicine, Vancouver General HospitalUniversity of British Columbia, British Columbia Cancer AgencyVancouverCanada

Personalised recommendations